Sunitinib in a 2/1 Schedule Safer for mRCC, Another Study Suggests

Share this content:
Sunitinib administered with a 2/1 schedule is associated with lower toxicity and higher 6-month failure-free survival rate than a 4/2 schedule.
Sunitinib administered with a 2/1 schedule is associated with lower toxicity and higher 6-month failure-free survival rate than a 4/2 schedule.

Sunitinib administered with a 2/1 schedule is associated with less toxicity and higher 6-month failure-free survival rate than a 4/2 schedule, without a negative effect on objective response rate and time to progression, in patients with clear-cell metastatic renal cell carcinoma (mRCC), a new study published online ahead of print in the journal Annals of Oncology has shown.1

Because the standard sunitinib schedule of 4 weeks on and 2 weeks off (4/2 schedule) is associated with troublesome toxicities, researchers sought to assess the efficacy and safety of a 2/1 sunitinib dosing schedule compared with the standard 4/2 schedule.

In the multicenter, open-label, phase 2, trial, researchers enrolled 74 treatment-naïve patients with clear-cell type mRCC and randomly assigned them to receive sunitinib in a 4/2 or 2/1 schedule.

RELATED: "Real-World" Survival for Renal Cell Carcinoma Patients Improving

Results showed that the 6-month failure-free survival rate was 44% with the 4/2 schedule and 63% with the 2/1 schedule. Objective response rates were 47% and 36% in schedule 2/1 and 4/2, respectively, and the median time to progression was 12.1 months and 10.1 months, respectively.

In regard to safety, neutropenia and fatigue were more frequently observed with schedule 4/2, and researchers observed a strong tendency of a lower incidence of rash, stomatitis, and hand-foot syndrome with schedule 2/1.

Reference

  1. Lee JL, Kim MK, Park I, et al. Randomized phase 2 trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial [published online ahead of print September 7, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv357.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters